14.38
Schlusskurs vom Vortag:
$14.75
Offen:
$14.71
24-Stunden-Volumen:
73,494
Relative Volume:
0.86
Marktkapitalisierung:
$135.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-81.17M
KGV:
-1.4189
EPS:
-10.1344
Netto-Cashflow:
$-82.84M
1W Leistung:
-17.55%
1M Leistung:
-34.01%
6M Leistung:
-57.19%
1J Leistung:
-79.86%
Korro Bio Inc Stock (KRRO) Company Profile
Firmenname
Korro Bio Inc
Sektor
Branche
Telefon
617-468-1999
Adresse
60 FIRST STREET, CAMBRIDGE
Vergleichen Sie KRRO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
KRRO
Korro Bio Inc
|
14.38 | 135.01M | 0 | -81.17M | -82.84M | -10.13 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-01-10 | Eingeleitet | Oppenheimer | Outperform |
2024-10-21 | Eingeleitet | Raymond James | Strong Buy |
2024-08-14 | Eingeleitet | William Blair | Outperform |
2024-03-28 | Bestätigt | H.C. Wainwright | Buy |
2024-02-27 | Eingeleitet | BMO Capital Markets | Outperform |
2023-12-04 | Eingeleitet | H.C. Wainwright | Buy |
2023-11-29 | Eingeleitet | RBC Capital Mkts | Outperform |
2023-11-10 | Eingeleitet | Piper Sandler | Overweight |
2023-02-15 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
2023-02-13 | Herabstufung | Cowen | Outperform → Market Perform |
2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
2021-01-27 | Hochstufung | JP Morgan | Neutral → Overweight |
2020-12-22 | Eingeleitet | B. Riley Securities | Buy |
2020-07-14 | Eingeleitet | Oppenheimer | Outperform |
2020-05-18 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-10-28 | Eingeleitet | Cowen | Outperform |
2019-10-28 | Eingeleitet | Goldman | Buy |
2019-10-28 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Korro Bio Inc Aktie (KRRO) Neueste Nachrichten
Korro Bio appoints new Chief Scientific Officer By Investing.com - Investing.com South Africa
Korro Bio appoints new Chief Scientific Officer - Investing.com
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer - The Manila Times
RNA-Editing Pioneer Korro Bio Lands Elite CSO with 20+ Drug Development Success Record - Stock Titan
Korro Bio: Promising Early Stage RNA Editing Company (NASDAQ:KRRO) - Seeking Alpha
Korro Bio reappoints CFO, names new principal accounting officer By Investing.com - Investing.com Canada
Korro Bio CFO Returns from Medical Leave - TipRanks
Korro Bio reappoints CFO, names new principal accounting officer - Investing.com
Korro Bio Inc Vineet Agarwal Ends Temporary Medical Leave As CFO - MarketScreener
Research Analysts Set Expectations for Korro Bio Q1 Earnings - Defense World
Q1 Earnings Forecast for Korro Bio Issued By William Blair - Armenian Reporter
HC Wainwright Reiterates Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World
Q1 Earnings Estimate for Korro Bio Issued By William Blair - Defense World
Royal Bank of Canada Has Lowered Expectations for Korro Bio (NASDAQ:KRRO) Stock Price - Defense World
Korro Bio Reports 2024 Financial Results and Progress - TipRanks
H.C. Wainwright maintains Buy rating on Korro Bio stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains Buy rating on Korro Bio stock - Investing.com
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Korro Bio’s SWOT analysis: RNA editing firm’s stock poised for growth - Investing.com Australia
Korro Bio’s SWOT analysis: RNA editing firm’s stock poised for growth By Investing.com - Investing.com South Africa
Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth? - Yahoo Finance
RBC Cuts Price Target on Korro Bio to $95 From $105, Keeps Outperform, Speculative Risk - Marketscreener.com
Korro Bio’s Promising Growth: Buy Rating Backed by Positive KRRO-110 Trial Progress and Market Opportunities - TipRanks
Korro Bio, Inc. SEC 10-K Report - TradingView
Korro Reports Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
Korro Bio Reports Clean Safety Data in AATD Drug Trial, Secures $163M Runway - StockTitan
Korro Bio (KRRO) Projected to Post Earnings on Tuesday - Defense World
FDA grants orphan drug status to Korro’s AATD treatment By Investing.com - Investing.com Australia
Korro Bio gets FDA Orphan Drug tag (KRRO:NASDAQ) - Seeking Alpha
Korro Bio's Potential Antitrypsin Deficiency Treatment Receives US FDA Orphan Drug Designation - Marketscreener.com
FDA grants orphan drug status to Korro’s AATD treatment - Investing.com
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency - The Manila Times
Breakthrough for Rare Disease: FDA Awards Special Status to Korro Bio's Novel RNA Treatment - StockTitan
Rhumbline Advisers Purchases 691 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
What Will Korro Bio Reveal at the TD Cowen Healthcare Conference Next Week? - StockTitan
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Rating of “Buy” from Analysts - Defense World
KRRO stock touches 52-week low at $28.71 amid market challenges - Investing.com Nigeria
Korro Bio CFO takes medical leave, interim officers appointed - MSN
Korro Bio CFO takes medical leave, interim officers appointed By Investing.com - Investing.com Nigeria
Korro Bio Appoints Interim CFO Amid Medical Leave - TipRanks
Korro Bio, Inc. Appoints Oliver Dolan as Interim Principal Accounting Officer -February 11, 2025 at 04:05 pm EST - Marketscreener.com
KRRO stock touches 52-week low at $29.8 amid yearly slump - Investing.com
AllianceBernstein L.P.'s Strategic Acquisition of Korro Bio Inc Shares - GuruFocus.com
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
JPMorgan Chase & Co. Boosts Stock Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Korro Bio, Inc. (NASDAQ:KRRO) Shares Bought by JPMorgan Chase & Co. - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Buy” from Analysts - Defense World
Korro Bio (NASDAQ:KRRO) Doses First Participants in REWRITE Phase 1/2a Clinical Study – Pipeline Update ProvidedOn January 13, 2025, Korro Bio, Inc. issued a press release stating that it had initiated dosing the first participants in its REWRITE Pha - Defense World
Finanzdaten der Korro Bio Inc-Aktie (KRRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):